Almac, Merck KGaA Partner on Cetuximab Markers

The partners will assess potential biomarkers, beyond KRAS, of response to cancer drug cetuximab (Erbitux).

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.